CYChun-Ting Yuen

Chun-Ting Yuen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chun-Ting Yuen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2008
      • Vol. 2008  (1) , 9-16

    Glycan mapping of glycotherapeutics.

    by C-T Yuen, A Bristow, C Jones

    Glycosylation of proteins may, or may not, affect biological activity, either directly or indirectly. In addition, variability in glycosylation arises within the manufacturing procedure. Therefore, glycosylation would be an important parameter when assessing product quality. Regulatory authorities require biotechnological and biological products to be characterised, including determination of their biological activity, physicochemical and immunochemical properties, their purity and their impurity profiles. Here we outline how we can decide if and which types of glycan analysis and methodologies to use for glycoprotein therapeutics to answer the scientific questions as well as meeting regulatory requirements that already exist or are going to be developed/implemented.

  • A Fluorescent Peptide Substrate for Measuring the ADP-Ribosylation Activity of the Cholera Toxin A-Subunit

    by Chun-Ting Yuen, Sjoerd Rijpkema

    Vibrio cholerae serogroups O1 and O139 Bengal produce cholera toxin (CT) a typical AB5 bacterial toxin comprising an ADP-ribosylation enzyme A-subunit (CTA) and a carbohydrate binding B-subunit (CT...


  • Relationships between the N‐glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures

    by Chun‐Ting Yuen, Patrick L Storring, Richard J. Tiplady, Mabel Izquierdo, Robin Wait, Christopher K. Gee, Peter Gerson, Pauline Lloyd, Jos A. Cremata

    Summary. Eight preparations of recombinant human erythropoietin (EPO) with differing isoform compositions were produced by using different culture conditions and purification procedures. The N‐glycan structures of these EPOs were analysed using a recently developed profiling procedure and identified using matrix‐assisted laser desorption ionization mass spectrometry. The specific activities of each of the EPOs were estimated by in vivo and in vitro mouse bioassays. The eight EPOs were found to differ in their isoform compositions (as judged by isoelectric focusing), their N‐glycan profiles, and in their in vivo and in vitro bioactivities. N‐glycan analyses identified at least 23 different structures among these EPOs, including bi‐, tri‐ and tetra‐antennary N‐glycans, with or without fucosylation or N‐acetyllactosamine extensions, and sialylated to varying degrees. Mass spectrometry also indicated the presence of N‐glycans with incomplete outer chains, terminating in N‐acetylglucosamine residues, and of molecular masses consistent with phosphorylated or sulphated oligomannoside structures. The tetrasialylated tetra‐antennary N‐glycan contents of the eight rEPOs were found to be significantly and positively correlated with their specific activities as estimated by mouse in vivo bioassay, and significantly and negatively correlated with their specific activities as estimated by mouse in vitro bioassay. It was concluded that the tetrasialylated tetra‐antennary N‐glycan content of EPO is a major determinant for its in vivo biological activity in the mouse.


  • Detection of residual pertussis toxin in vaccines using a modified ribosylation assay

    by Chun-Ting Yuen, Catpagavalli Canthaboo, J.ALan Menzies, Terry Cyr, Larry W Whitehouse, Chris Jones, Michael J Corbel, Dorothy Xing


  • High‐performance liquid chromatographic profiling of fluorescent labelled N‐glycans on glycoproteins

    by C.‐T. Yuen, C. K. Gee, C. Jones

    Monitoring protein glycosylation is becoming increasingly important as novel recombinant glycoprotein therapeutics, such as glycoprotein hormones, cytokines and clotting factors, are introduced into clinical use. In this report, we describe an HPLC strategy and an improved and simplified pre‐column derivatization procedure to profile N‐linked glycans obtained from a variety of commercially available glycoproteins as examples. N‐Glycans were first released by peptide:N‐glycosidase F and labelled with the fluorescent label, 4‐aminobenzoic acid by reductive amination. The labelled N‐Glycans were then resolved by normal‐phase HPLC and the N‐glycan profile could be further improved by separating the N‐glycans first according to charge by anion‐exchange HPLC prior to the normal‐phase HPLC. If required, identification of the fractionated derivatized oligosaccharides can be determined by mass spectrometry. The whole profiling process is simple and can be implemented in most laboratories. Because of the high sensitivity, batch glycan‐analysis of low‐yield recombinant glycoproteins such as samples in ampoules or obtained in the early stage of production development is possible. Copyright © 2002 John Wiley & Sons, Ltd.